| [1] PubMed ID: | 32565910 |
| Disease Name: | Atherosclerosis |
| Sample: | AS tissues |
| Dysfunction Pattern: | regulation[miR-141-3p/ROR2 Axis] |
| Validated Method: | Western Blot//qRT-PCR//MTT//Luciferase Report Assay//Transwell Assay |
| Description: | The expression of TUG1 and ROR2 was promoted in AS tissues and ox-LDL-treated HA-VSMCs. TUG1 enhanced the progression of AS in vitro by regulating the miR-141-3p/ROR2 axis. |
| Causality: | Yes |
| Causal Description: | Silencing of TUG1 inhibited the proliferation, migration, invasion, and metastasis in ox-LDL-treated HA-VSMCs. |
| Clinical-realted Application: | |
| [2] PubMed ID: | 34646415 |
| Disease Name: | Atherosclerosis |
| Sample: | atherosclerotic serum samples and a cell model |
| Dysfunction Pattern: | Interaction(miR-382-5p) |
| Validated Method: | CCK8//qRT-PCR//Transfection//Luciferase Report Assay |
| Description: | TUG1 and miR-382-5p expressions were significantly increased and decreased, respectively, in both atherosclerotic serum samples and a cell model. In addition, the expression of TUG1 was negatively correlated with the level of miR-382-5p in atherosclerotic serum samples. Notably, a miR-382-5p inhibitor significantly reversed the effect of TUG1 downregulation on ox-LDL-treated VSMCs, which aggravates the process of atherosclerosis. |
| Causality: | Yes |
| Causal Description: | Moreover, silencing of TUG1 reduced cell growth and enhanced the apoptosis of ox-LDL-treated VSMCs. |
| Clinical-realted Application: | |
|